GlycoVaxyn AG enters Strategic Collaboration with GSK to Develop New Bacterial Vaccines VISCHER advises GlycoVaxyn, a leader in the development of innovative vaccines, entering into a collaboration…
Anergis closes financing round totaling CHF 8 million VISCHER advises Anergis in Lausanne, a company discovering and developing proprietary al-lergy vaccines, in a financing round totaling CHF 8…
ProteoMediX closes Series B Financing VISCHER advises ProteoMediX Raises in its CHF 3.2 million in Series B Financing. ProteoMediX, in Schlieren, is a diagnostic company developing non-invasive…
Acquisition of Mind-NRG by Minerva Neurosciences VISCHER advises Mind-NRG, in Geneva, in the sale of Mind-NRG to Minerva Neurosciences. Mind-NRG's main asset is MIN-301, a compound in development…
Mallinckrodt plc acquires Cadence Pharmaceuticals, Inc. Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, acquires Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) for…
Covagen closes 42 Mio financing round VISCHER advises Covagen in its Series B financing of CHF 42 million. The Series B includes an option for all existing investors to invest an additional CHF 14…
Sonetik closes financing to fund further growth in the US VISCHER advises Sonetik in a financing to fund further growth in the US. The participants in this Series A2 financing include existing…
Loomis acquires VIA MAT VISCHER advises Loomis, one of the leading cash handling companies, as to Swiss law in ist 100% acquisition of VIA MAT Holding AG ("VIA MAT"). VIA MAT is one of the world?s…
Airbus Sale and Lease-Back Transaction VISCHER advises Beijing based Minsheng Financial Leasing Co. Ltd. in a sale and lease back transaction of an Airbus aircraft registered in Switzerland from Air…
Baxter Ventures invests in Covagen Covagen adds Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million with an option to extend this to CHF 58.9 Mio.…
